Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (AIM) is a clinical-stage biopharmaceutical company pioneering RNA-based therapeutics for cancer, viral diseases, and immune disorders. This dedicated news hub provides investors and researchers with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access verified information about Ampligen clinical progress, Alferon N Injection research, and collaborative studies with global institutions. Our curated news collection covers FDA communications, trial phase results, intellectual property updates, and scientific conference presentations.
Key updates include oncology treatment advancements, antiviral therapy research, and partnership announcements with organizations like Japan's National Institute of Infectious Diseases. Bookmark this page for real-time access to AIM's latest developments in immuno-pharmaceutical innovation.
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced the opening of enrollment in a Phase 1b/2 clinical trial at Erasmus Medical Center in Rotterdam, Netherlands, for the treatment of pancreatic cancer. The trial will combine AIM's Ampligen with AstraZeneca's Imfinzi, aiming to determine the safety and clinical benefit rate of the combination therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) announces the election of all four directors at the 2023 Annual Meeting of Stockholders. The company expresses gratitude to shareholders and emphasizes commitment to delivering life-saving treatments and creating shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
-
Rhea-AI Summary
Court Found that Several AIM Advance Notice Bylaws Are Invalid. The Delaware Court of Chancery ruled in favor of the Kellner Group, finding four separate advance notice bylaw provisions adopted by AIM Immunotech Inc. to be invalid. However, the Court also found that Mr. Kellner's notice of nominations did not comply with certain remaining advance notice provisions. AIM announced that it will disregard the Kellner Group's nominations, and any proxies voted in favor of the Kellner Group nominees will not be recognized or tabulated at the Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced the Delaware Court of Chancery ruled against the Activist Group's nomination notice, finding it invalid under the Company's Bylaws. The Court upheld the Board's decision to reject the notice due to omissions and misleading information. AIM will reconvene its 2023 Annual Meeting and adjourn until January 5th, disregarding any proxies submitted by the Activist Group. The Board urges shareholders to vote for all four Company Directors on the WHITE Proxy Card.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) will convene its 2023 Annual Meeting of Stockholders on December 1st, adjourning until December 29th to await a ruling from the Delaware Court of Chancery regarding litigation brought against the Company and its directors by an Activist Group seeking to nominate three candidates for election to AIM's Board of Directors. The Board has determined the Activist Group's nomination notice as invalid and will disregard any proxies or votes cast for the individuals on the Activist Group's proxy card unless the litigation results in a finding that the Notice is valid. The record date for determining shareholders eligible to vote at the 2023 Annual Meeting remains October 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) extends exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 with the issuance of U.S. patents No. 11,813,279 and 11,813,281. The patents cover novel methods for cancer therapy and improving exercise tolerance in ME/CFS patients. AIM's CEO, Thomas K. Equels, emphasizes the potential financial future of the company and the driving force behind multiple clinical studies in oncology, ME/CFS, and Post-COVID conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) announced the completion of dosing in the Phase 2 study for Ampligen® as a potential therapeutic for Post-COVID fatigue. No severe adverse events reported. Topline data expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
-
Rhea-AI Summary
AIM Immunotech Inc. (NYSE American: AIM) - The Kellner Group urges stockholders to act against the entrenched Board's reckless spending and self-interested behavior. The Board has wasted $15 million in the past two years to prevent stockholders from voting on Board nominations and has failed to engage in dialogue to avoid this destructive and wasteful path. The Kellner Group, owning 6.5% of outstanding shares, is fully aligned with stockholders and brings the skills, experience, and credibility necessary for AIM to succeed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) reported financial results for Q3 2023 and provided a business update, highlighting progress in the Ampligen® clinical development programs. The company aims to achieve value-driving milestones in ovarian and pancreatic cancer programs. Recent highlights include encouraging translational data from an ongoing Phase 2 clinical trial in ovarian cancer and engaging a business development consulting firm to partner pipeline programs. Financially, AIM reported $22.4 million in cash, with increasing R&D and G&A expenses. The company will host a conference call and webcast on November 15, 2023, to discuss operational and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announces the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy. The study evaluated the safety and the combination's ability to promote local CTL influx to mTNBC lesions. The data were published in The Journal for ImmunoTherapy of Cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
Aim Immunotech
NYSE:AIM
AIM Rankings
AIM Stock Data
6.52M
67.24M
10.11%
12.54%
4.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
OCALA